The Drug Eluting Stent Market is Predict to reach $13.2 Billion by 2030, at a CAGR of 8.4%

Drug Eluting Stent Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Drug Eluting Stent Market size is expected to reach $13.2 billion by 2030, rising at a market growth of 8.4% CAGR during the forecast period. In the year 2022, the market attained a volume of 14,030.2 thousand units, experiencing a growth of 7.8% (2019-2022).

The Coronary Artery Disease segment is leading the Global Drug Eluting Stent Market by Application in 2022; thereby, achieving a market value of $10.8 billion by 2030. Due to the expanding global prevalence of coronary artery disease (CAD), a severe cardiovascular problem, the coronary artery disease segment is dominant in the drug eluting stent market. DES has proved to be a highly effective method for treating coronary artery disease, offering patients a quick and effective treatment option. These factors will prove beneficial for the segment’s expansion.

The Polymer-free Coating segment would register a CAGR of 9.8% during (2023 - 2030). The promise of polymer-free coatings to address long-term issues related to conventional polymer-based coating drives their demand in the drug eluting stent market. Polymer-free coatings have demonstrated the potential to reduce the chance of slow healing and subsequent adverse outcomes like restenosis and thrombosis.

The North America region dominated the Global Drug Eluting Stent Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $5.0 billion by 2030. The Europe region is anticipated to grow at a CAGR of 8.1% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 9.4% during (2023 - 2030).

Full Report: https://www.kbvresearch.com/drug-eluting-stent-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.), Cook Medical, Inc. (Cook Group), B. Braun Melsungen AG, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd and Alvimedica.

Global Drug Eluting Stent Market Segmentation

By Application (Volume, Thousand Units, USD Million, 2019-2030)

• Coronary Artery Disease
• Peripheral Artery Disease

By Coating Type (Volume, Thousand Units, USD Million, 2019-2030)

• Polymer-based Coating
  • Non-biodegradable Polymers
  • Biodegradable Polymers
• Polymer-free Coating
  • Micro Porous Surface
  • Micro Structured Surface
  • Slotted Tubular Surface
  • Nanoporous Surface

By Geography (Volume, Thousand Units, USD Million, 2019-2030)

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• Boston Scientific Corporation
• Terumo Corporation
• Medtronic PLC
• Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.)
• Cook Medical, Inc. (Cook Group)
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Lepu Medical Technology Co., Ltd
• Alvimedica

Related Reports:

North America Drug Eluting Stent Market Size & Share to 2030

• September-2023
• 130 Pages

LAMEA Drug Eluting Stent Market Size, Share & Growth, 2030

• September-2023
• 148 Pages

Europe Drug Eluting Stent Market Size & Industry Trends 2030

• September-2023
• 149 Pages

Asia Pacific Drug Eluting Stent Market Size & Forecast 2030

• September-2023
• 149 Pages